Jan 04 2022: Reference standard became available after the 12-month storage period lapsed for the sample. It won't be re-analyzed.
May 14 2020: Sample was re-analyzed and compared to the standard for the more common 2'-Chlorodiazepam (Diclazepam), which has a very similar mass spectrum, different ion ratio and slightly different retention time. Result: Diclazepam has been ruled out.
May 10 2020: This sample will be re-analyzed once a reference standard has been ordered and the lab receives it. Check back here for an update.
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our DEA-licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
Diclazepam (2'-Chlorodiazepam) ruled out.
Sender comments that prior to sending this in, 'Reagent testing yielded unexpected results.'
May 14 2020: Sample was re-analyzed and compared to the standard for the more common 2'-Chlorodiazepam (Diclazepam), which has a very similar mass spectrum, different ion ratio and slightly different retention time.
Result: Diclazepam has been ruled out.
May 10 2020: This sample will be re-analyzed once a reference standard has been ordered and the lab receives it. Check back here for an update.